Side Effects of Dog Allergy Shots: Reactions and the Extract Quality Problem

The fundamental difference comes down to extract standardization. Cat allergen extract (Fel d 1) is FDA-standardized — manufacturers must verify allergen potency in standardized BAU units, meaning a given concentration delivers a consistent dose regardless of which company produced it. Dog allergen extract is not FDA-standardized. It is measured in PNU/mL or weight-to-volume ratios, and the content of Can f 1 — the major dog allergen — has been shown to vary more than 100-fold across commercial preparations (Uhlin et al., JACI 1984). This variability means that vial-to-vial transitions for dog extract introduce more potency uncertainty than for cat extract, potentially producing unexpected reaction patterns even at doses a patient had previously tolerated. Additionally, Can f 5 — a major dog allergen affecting approximately 70% of dog-allergic patients — is often absent from commercial extracts, creating incomplete immunotherapy coverage for a substantial portion of treated patients.

Can f 5 is prostatic kallikrein — a protein allergen produced in the prostate of intact male dogs and present in their urine, saliva, and dander. It is a significant allergen for approximately 70% of dog-allergic patients (Mattsson et al., JACI 2009). The clinical importance: Can f 5 is often absent from commercial dog allergen extract preparations. If you are sensitized to Can f 5 and your extract does not contain it, your allergy shots may be delivering incomplete immunotherapy — training tolerance to some dog proteins but not the one responsible for a significant portion of your symptoms. This is particularly relevant for patients who react more severely to male dogs than female dogs, or who notice their allergy symptoms are worse around intact male dogs specifically. Before starting dog allergy shots, ask your allergist whether your allergy test measured Can f 5 sensitization specifically and whether your prescribed extract is known to contain this allergen.

Yes — living with a dog during allergy shot treatment is not a contraindication, and most dog-allergic patients who pursue immunotherapy do so while continuing to live with their pets. However, ongoing natural allergen exposure during the build-up phase may increase baseline symptoms — you may experience more pronounced respiratory symptoms during the initial weeks of build-up than you would if the dog were removed from the environment. Allergists typically recommend concurrent environmental controls: HEPA air purifiers in bedrooms and main living areas, keeping the dog out of the bedroom, regular bathing of the dog (reduces Can f 1 shedding by approximately 60% for 1-2 weeks), and regular hand washing after dog contact. These measures reduce the constant high-level allergen exposure that can overlap with and confound immunotherapy build-up reactions. Keeping a symptom diary during build-up helps distinguish immunotherapy side effects from ongoing dog-allergen exposure symptoms.

Injection-site local reactions typically resolve within hours to a day. A small wheal and mild redness at the injection site resolve within a few hours. Late-phase swelling, which can appear 6-12 hours after the injection and peak at 24-48 hours, typically resolves over 1-5 days depending on size. These reactions are expected and self-limiting — they do not indicate that dog SCIT is failing or that you are having a dangerous reaction. Systemic reactions, if they occur, require evaluation before the next injection and dose adjustment. The pattern of local reactions often changes during the course of dog SCIT: reactions may intensify as doses increase during build-up, then stabilize or improve once maintenance is reached. The non-standardized nature of dog extract means that reactions can also shift at vial transitions in ways that would be less likely with a standardized extract.

Efficacy of dog allergy shots is genuinely complicated by extract quality concerns. The limited RCT evidence — Valovirta 1986 (12/15 patients improved) and Alvarez-Cuesta 2020 (high-dose dog SCIT, n=20, showing clinical improvement when adequate dosing was achieved) — supports that dog SCIT can work when dosing is sufficient and the extract adequately represents the patient's sensitization profile. The challenge: if you are sensitized to Can f 5 and your extract does not contain it, or if Can f 1 content is low due to manufacturer variability, your shots may produce partial or no benefit for those specific allergen components. Some patients experience treatment failure from dog SCIT not because shots don't work, but because the extract being used doesn't deliver the allergens driving their symptoms. Discussing extract source, standardization approach, and allergen component coverage with your allergist before starting treatment is worthwhile for setting realistic expectations.

Many SCIT patients are polysensitized — allergic to dog plus dust mite, mold, cat, grass, or other allergens — and receive multi-allergen extracts in combined vials. For dog extract specifically, one important mixing rule applies: dog dander extract should NOT be combined with protease-rich extracts such as mold (Alternaria, Cladosporium), cockroach, or dust mite in the same vial (Grier 2007). Proteases in mold and some mite extracts can degrade dog and cat proteins in solution, reducing allergen potency and potentially altering the extract's immunological activity. This issue applies specifically to liquid vial mixing — it is a formulation concern, not a reaction risk per se. Your allergist's office should be aware of this incompatibility and separate protease-rich extracts into a different vial. If you receive two separate vials at your injection appointments, this is likely why.